Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. - Wikidata - wikimedia - TriplyDB

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study.

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study.

http://www.wikidata.org/entity/Q39360937

about

Rasagiline for levodopa-induced motor complications in Parkinson´s disease Piribedil for levodopa-induced complications in Parkinson's disease Piribedil versus levodopa in early Parkinson's disease Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Dopamine agonists in Parkinson's disease Neuropathy in Parkinson's disease patients with intestinal levodopa infusion versus oral drugs Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study.Nonergot dopamine-receptor agonists for treating Parkinson's disease - a network meta-analysis.New small molecules for the treatment of Parkinson's disease.Pharmacotherapy in Parkinson's disease: case studies.Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist Seniors with Parkinson's disease: initial medical treatment.Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.How to optimize the treatment of early stage Parkinson's disease.Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?Patient considerations in early management of Parkinson's disease: focus on extended-release pramipexole Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease.Clinical aspects and management of levodopa-induced dyskinesia.Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.Role of dopamine agonists in Parkinson's disease: an update.Protection against Parkinson's disease progression: clinical experience.Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.Levodopa in the treatment of Parkinson's disease: an old drug still going strong.Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.Milestones in Parkinson's disease therapeutics.Pramipexole extended release in Parkinson's disease.Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.The impact of subthalamic deep brain stimulation on nigral neuroprotection-myth or reality?The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease.Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.Treatment in early Parkinson's disease: the Norwegian ParkWest study.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease.Novel levodopa formulations in the treatment of Parkinson's disease.Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson's disease: a meta-analysis.

P2860

Q24243502-A858B81A-F207-46BD-93FA-5C78FA784EA7 Q24244549-D42EDF64-E0CF-48B4-8F53-4BD0051178EA Q24244961-4E1B0278-0794-4DA3-8FC8-E4A4EDF2FFB0 Q27021464-C01BBECB-818B-4E0B-8DF6-F3E34FF53D4F Q28276692-1626678D-A121-46C9-8FD0-05F949E6EA91 Q28534024-577A9830-DEF1-4628-8779-B77D624943BB Q33260250-282F9AB9-1E41-40D0-8CC1-C21519C39FBC Q33465315-BCD3A265-8C52-4FB0-8A07-F23F79F4B169 Q33604937-E0B0FA0C-45AA-40D5-BC26-3310E8FEDB21 Q33636631-B3F0BA6F-75A8-48AB-90D5-5C0DE28F4A70 Q34409459-0A985E4F-D468-4E6B-AA72-E7F6B846B235 Q34504316-1A7BBBEE-A984-499E-BEB9-8D644FD3234C Q34508143-A088A4A9-756B-4BFD-A907-A117069757A8 Q35016008-F4DAA325-85C4-42D8-8FC1-F6E6CB443FDE Q35589979-4A8792F8-C16F-450A-8871-BF7E6F2F0864 Q35599297-7B48AFD0-3DED-41AB-980D-1428256DB09D Q35654026-759CBDDE-6A6B-4682-9701-F46BEB51FA24 Q35716858-46ABF3A6-5CDD-4278-8A7A-E3DBE206C261 Q35885133-0DF168A6-370F-41CD-AE3D-5EF745DDF4F1 Q36022700-B6A93951-F2D7-45C7-9D92-B578D77F8619 Q36573882-34F83F71-5C51-4962-98F9-D67E7CF8B7DB Q36972701-A8309B46-763F-4CC6-9353-372ABC99AF5D Q37131239-96C6F207-56BA-4A01-BDA6-BDC509383E48 Q37736512-5070BE21-2D07-409D-A6DA-77B44D85A10F Q37776519-DE8F2254-10B4-4576-ADD2-B412D5FEF662 Q37790274-603B7A5B-F30F-41F7-91BA-3B9FFC4207C7 Q37831397-8458F404-B148-4938-A16C-A77DE33267E4 Q37882596-ECA03A13-FC79-4DF1-9256-A87762650F88 Q37921759-71252325-93EE-4C41-B3D2-5C8FEB29F349 Q37924626-B2650DB5-06F5-4A31-9014-D018BC1E6CF9 Q37944953-A1D67193-1D7A-4BDE-854C-BE818E1E968C Q37948713-AB8CCAA4-FA72-429C-8F49-371860539435 Q37973462-88D7B5CC-7888-4590-A403-32B515DE26CC Q37979869-92921DE0-226E-4792-A4A7-231FDC4BF794 Q38063341-D30F0193-13D1-45D4-9A63-60DC2C0C57CA Q38070888-377DEF18-EBE3-4E4A-A396-42620359EE14 Q38112217-FD597345-423C-47C8-AF01-29A34B2CDC47 Q38178754-899FF809-D82C-48A1-A999-218989E6565C Q38314257-65D55ABD-F200-4656-8E24-1FBF998BA2B9 Q38485023-30827722-87B5-4991-8EE7-CA92FF2A6428

P2860

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study.

http://www.wikidata.org/entity/Q39360937

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Pergolide versus levodopa mono ...... patients: The PELMOPET study.

@en

Pergolide versus levodopa mono ...... patients: The PELMOPET study.

@nl

type

label

Pergolide versus levodopa mono ...... patients: The PELMOPET study.

@en

Pergolide versus levodopa mono ...... patients: The PELMOPET study.

@nl

prefLabel

Pergolide versus levodopa mono ...... patients: The PELMOPET study.

@en

Pergolide versus levodopa mono ...... patients: The PELMOPET study.

@nl

P1433

Q39360937-C09F4953-B9BF-4C2D-9AE6-26759693DDF5

P1476

Q39360937-6D14D70E-FD1D-41A2-9165-2B0A55063345

P2093

Q39360937-279A2796-C0F1-4C9E-99A5-B921885409D3

Q39360937-38026263-F639-4B12-8CC6-2B18AE097605

Q39360937-564734B4-8346-40B0-931E-2BB9332C05A9

Q39360937-78C8CAD6-C287-4986-8FFB-50E834A6519E

Q39360937-8F0C5086-7D75-4A9A-83F2-C93F528267BE

Q39360937-9D4A80F4-C347-432F-9720-62AF1D5EF416

Q39360937-9E2C7AAE-BFEB-4AF0-96B8-2A148F70E4DE

Q39360937-AABECE7A-34FF-4106-A47B-D38801707401

Q39360937-D77A2E79-6299-4E28-9366-07F876DA8CDB

Q39360937-F28CE7F0-01DA-4A84-A1DE-EF9303B7B8E2

P304

Q39360937-1162454E-DBBC-473D-955B-EF10F2C07838

P31

Q39360937-EAC71C5E-6D17-4D0D-8343-4FB339AAEF26

P356

Q39360937-50C9A2B4-408D-47A9-97A8-8870EA1CF986

P407

Q39360937-CC8DB67A-26CA-4F89-A496-D515B1D0F576

P433

Q39360937-917CE388-E861-48F7-90D0-2280826CE6CA

P478

Q39360937-631B846D-D55B-401D-9985-F674FB101560

P50

Q39360937-060FB1A6-F463-445A-B104-2342D81DFFE6

Q39360937-919E6391-C6BB-4529-9353-214D14AEF2B4

P577

Q39360937-EDBB1510-B621-4EAD-B25D-9CE89E1CC08E

P698

Q39360937-133FB106-7225-49A8-B628-DF965A99D2D4

P921

Q39360937-7654BDB2-ABD7-4B2B-8E1C-15F87FB9020E

Q39360937-99D83905-F79B-475B-BC5B-A52A4C429781

Q39360937-BE8FF851-C0AD-4F4F-9CF9-403EB285CCEA

P356

P1433

Movement Disorders

P1476

Pergolide versus levodopa mono ...... patients: The PELMOPET study.

@en

P2093

Alberto Lledó

http://www.w3.org/2001/XMLSchema#string

Andrew Wood

http://www.w3.org/2001/XMLSchema#string

Bruno Bergamasco

http://www.w3.org/2001/XMLSchema#string

Donald G Grosset

http://www.w3.org/2001/XMLSchema#string

Erik Wolters

http://www.w3.org/2001/XMLSchema#string

Guy Arnold

http://www.w3.org/2001/XMLSchema#string

Hans-Peter Hundemer

http://www.w3.org/2001/XMLSchema#string

Johannes Schwarz

http://www.w3.org/2001/XMLSchema#string

Klaus L Leenders

http://www.w3.org/2001/XMLSchema#string

Max Dujardin

http://www.w3.org/2001/XMLSchema#string

P304

343-353

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.20724

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Wolfgang H. Oertel

Cristina Sampaio

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16211594

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease